Association of Serum C-Reactive Protein (CRP) with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Background: Chronic obstructive pulmonary disease consists of Chronic Bronchitis & Emphysema. It is persistent airflow limitation, usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung. The cause is tobacco smoking, occupational dusts, indoor and outdoor air pollutions. Objective: To find out association between serum C - reactive protein with acute exacerbation of Chronic Obstructive Pulmonary Disease. Methods: A Cross-sectional comparative study was carried out at Outpatient and inpatient department of Medicine and Respiratory unit of Z.H. Sikder womens Medical College & hospital, Dhaka, Bangladesh from 1 year (July-2020 to june-2021). A total number of 100 subjects of both sexes age range of 40-75 years who fulfilling inclusion and exclusion criteria & attending outpatient and inpatient departments of the Medicine and Respiratory unit of Z.H. Sikder womens Medical College & Hospital, Dhaka within the time frame. The study subjects were then divided into three groups Group I (AECOPD), Group II (SCOPD), and Group III (Control group). Results: A total number of 100 subjects of both sexes were included in this study in the age range of 40-75 years. Most of the subjects belong to 51-60- & 61-70-years age groups. The mean ages of group 1 were 59.4±9.0; group 2 was 59.4±6.7 and group 3 was 59.5±10.8 and the of total subjects' mean age was 59.5±8.4. Men had a higher prevalence of chronic obstructive pulmonary disease than women. In this study 85.4% of the patients of acute exacerbation of COPD were male and 14.6% were female. The ratio was 5.83:1. The common symptoms during exacerbation are increased dyspnoea (78%), increase cough (73%), increased sputum production (68%), change in sputum color (66%). The mean FEV1/FVC ratio in percentage was 45.5±9.7% in AECOPD; 68.5± 9.7% in stable COPD. The mean value of serum CRP was 16.9±4.4 in AECOPD (group-1); 10.9±3 in stable COPD (group-2) and 5.1±1.7 in case ...